Compare Cisco Systems Inc (CSCO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Johnson & Johnson — how do they compare? Cisco Systems Inc trades at $114.97 (market cap $452.96B), while Johnson & Johnson trades at $261.2 (market cap $618.09B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Johnson & Johnson for 129 Days on average.
| CSCO | JNJ | |
|---|---|---|
Market Cap | $452.96B | $618.09B |
Volume | 12,951,578 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $130.00 | $278.43 |
52-Week Low | $67.46 | $186.00 |
Typical Hold Time | 86 Days | 129 Days |
Enterprise Value | $466.58B | $646.37B |
Dividend Yield | 1.46% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $117.39, down 0.47% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.22, and revenue growth is supported by AI-driven networking demand. Valuation ratios are elevated with a P/E of 34.5, while profitability remains robust with a net income margin of 20.95%.
The outlook is positive given AI infrastructure growth and consistent earnings beats, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $129.77 price target, implying potential upside. Key risks include execution challenges in integrating AI innovations and macroeconomic sensitivity.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
